Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–736.
   PubMed Web of Science ®Google Scholar
• Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985–2013: a population-based, registry linkage study. Lancet HIV. 2018;5(11):e647–e655.
   PubMed Web of Science ®Google Scholar
• Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma–diagnosis and treatment. Lancet Oncol. 2004;5(1):19–26.
   PubMed Web of Science ®Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review 1975–2017 based on November 2019 SEER data submission, posted to the SEER web site. [accessed 07 Jan 2021]. Available from https://seer.cancer.gov/csr/1975_2017/
   Google Scholar
• Han X, Jemal A, Hulland E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. Cancer Epidemiol Biomarkers Prev. 2017;26(3):303–311.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373(26):2499–2511.
   PubMed Web of Science ®Google Scholar
• Keegan THM, Bleyer A, Rosenberg AS, et al. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–1557.
   PubMed Web of Science ®Google Scholar
• Keegan THM, Li Q, Steele A, et al. Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. Cancer Causes Control. 2018;29(6):551–561.
   PubMed Web of Science ®Google Scholar
• Schonfeld SJ, Gilbert ES, Dores GM, et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst. 2006;98(3):215–218.
   PubMedGoogle Scholar
• Specht L, Yahalom J, Illidge T, ILROG, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Sud A, Thomsen H, Sundquist K, et al. Risk of second cancer in Hodgkin lymphoma survivors and influence of family history. J Clin Oncol. 2017;35(14):1584–1590.
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239–4246.
   PubMed Web of Science ®Google Scholar
• Giri S, Pathak R, Martin MG, et al. Incidence of breast cancer among female survivors of Hodgkin lymphoma: a US-population-based trend analysis from 1973 to 2011. Blood. 2015;126(15):1861–1863.
   PubMed Web of Science ®Google Scholar
• Kumar V, Garg M, Chandra AB, et al. Trends in the risks of secondary cancers in patients with Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(9):576–589.e571.
   PubMed Web of Science ®Google Scholar
• Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100(6):1989–1996.
   PubMed Web of Science ®Google Scholar
• Abe J, Andrews P, Bedard A, et al. The SEER program code manual. In: Fritiz A, Ries L, editors. Surveillance, epidemiology, and end results program. 1998.
   Google Scholar
• Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2013.
   Google Scholar
• SEER*Stat software. Multiple primary-standardized incidence ratios (MP-SIR), release 8.3.6.1. Bethesda (MD), 2019.
   Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• Mulder RL, Hudson MM, Bhatia S, et al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the international guideline harmonization group. J Clin Oncol. 2020;38(35):4194–4207.
   PubMedGoogle Scholar
• Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55(9):1228–1235.
   PubMed Web of Science ®Google Scholar
• Lurain K, Yarchoan R, Ramaswami R. The changing face of HIV-Associated malignancies: advances, opportunities, and future directions. Am Soc Clin Oncol Educ Book. 2019;39:36–40.
   PubMedGoogle Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.
   PubMed Web of Science ®Google Scholar
• Worm SW, Bower M, Reiss P, et al. Non-AIDS defining cancers in the DAD study-time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013;13:471.
   PubMed Web of Science ®Google Scholar
• Park LS, Hernández-Ramírez RU, Silverberg MJ, et al. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a Meta-analysis. AIDS. 2016;30(2):273–291.
   PubMed Web of Science ®Google Scholar
• Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017;65(4):636–643.
   PubMed Web of Science ®Google Scholar
• Kong CY, Sigel K, Criss SD, et al. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/μl. AIDS. 2018;32(10):1333–1342.
   PubMed Web of Science ®Google Scholar
• Makinson A, Tron L, Grabar S, et al. Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French hospital database on HIV cohort. HIV Med. 2020;21(3):180–188.
   PubMed Web of Science ®Google Scholar
• Robbins HA. Lung cancer screening in people living with HIV: modeling to bridge the evidence. AIDS. 2018;32(10):1369–1371.
   PubMed Web of Science ®Google Scholar
• Bull-Henry K, Morris B, Buchwald UK. The importance of anal cancer screening and high-resolution anoscopy to gastroenterology practice. Curr Opin Gastroenterol. 2020;36(5):393–401.
   PubMed Web of Science ®Google Scholar
• Stier EA, Chigurupati NL, Fung L. Prophylactic HPV vaccination and anal cancer. Hum Vaccin Immunother. 2016;12(6):1348–1351.
   PubMed Web of Science ®Google Scholar
• Reid E, Suneja G, Ambinder RF, et al. Cancer in people living with HIV, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(8):986–1017.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–715.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst. 1995;87(20):1530–1537.
   PubMedGoogle Scholar
• Robert SA, Strombom I, Trentham-Dietz A, et al. Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology. 2004;15(4):442–450.
   PubMed Web of Science ®Google Scholar
• Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49(10):1570–1578.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Koritzinsky EH, Clarke CA, et al. Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23(2):274–281.
   PubMed Web of Science ®Google Scholar